Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Lifecore Biomedical (LFCR) over the last 16 years, with Nov 2024 value amounting to $9.9 million.

  • Lifecore Biomedical's Other Accumulated Expenses rose 28.85% to $9.9 million in Q4 2024 from the same period last year, while for Nov 2024 it was $9.9 million, marking a year-over-year increase of 28.85%. This contributed to the annual value of $9.4 million for FY2024, which is 30.97% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Other Accumulated Expenses of $9.9 million as of Q4 2024, which was down 13.30% from $11.4 million recorded in Q3 2024.
  • In the past 5 years, Lifecore Biomedical's Other Accumulated Expenses registered a high of $13.0 million during Q1 2022, and its lowest value of $3.0 million during Q2 2021.
  • In the last 3 years, Lifecore Biomedical's Other Accumulated Expenses had a median value of $9.1 million in 2024 and averaged $8.9 million.
  • In the last 5 years, Lifecore Biomedical's Other Accumulated Expenses slumped by 69.84% in 2021 and then skyrocketed by 141.37% in 2022.
  • Over the past 5 years, Lifecore Biomedical's Other Accumulated Expenses (Quarterly) stood at $6.1 million in 2020, then tumbled by 36.55% to $3.9 million in 2021, then soared by 141.37% to $9.4 million in 2022, then declined by 18.24% to $7.7 million in 2023, then rose by 28.85% to $9.9 million in 2024.
  • Its last three reported values are $9.9 million in Q4 2024, $11.4 million for Q3 2024, and $9.4 million during Q2 2024.